ARCHIVES

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

NCI To Slow New Center Development To Assure Funding For Existing Commitments, King Says

February 14, 1975

NCI Advisors Approve $160-Million Network For Biomarker Discovery, Validation

March 13, 2009

Executive Summary of Centers, SPOREs Report

February 28, 2003

Bertagnolli: Why Brigham Stopped Making Morcellation Available Outside Of A Registry Trial

July 4, 2014

DeVita Suggest Chop Should Be Expanded, Given Long Term Status, But Only With A “Quid Pro Quo”

March 20, 1981

ASCO Entering Prime Of Life

May 31, 1991